Report
Arnaud Despre ...
  • Clément Bassat
  • Maxence Dhoury
  • Mohamed Kaabouni
  • Nicolas Delmas

La Matinale - 16-03-2023 - Portzamparc

BIOSENIC : Le viscosupplément JTA-004 abandonné en août 2021 refait surface – Acheter (1), obj. 0.52€ Cours: 0.13€ au 15/03/23
HOFFMANN GREEN : Nouvelle belle signature / Contact – Renforcer (2), obj. 17.0€ Cours: 8.17€ au 15/03/23
ID LOGISTICS : Une publication sans accroc – Acheter (1), obj. 400.0€ Cours: 281.5€ au 15/03/23
PHARMING GROUP : Prépare le lancement de leniolisib – Acheter, obj. 1.90€ Cours: 1.06€ au 15/03/23
VALBIOTIS : Des jalons importants attendus en 2023 – Acheter (1), obj. 12.9€ Cours: 4.14€ au 15/03/23
COLLECTE / DECOLLECTE : Retour à la tendance
Underlyings
Bone Therapeutics SA

Bone Therapeutics is a biotechnology company with an advanced clinical pipeline of cell products for orthopaedic conditions and bone diseases (two Phase II/III and three Phase I/II clinical studies). These areas are characterized by high unmet medical needs due to the lack of efficacious and safe, non-invasive, treatments. Co. has two products in clinical trials, its allogeneic bone cell therapy product, ALLOB®, and its autologous bone cell therapy product, PREOB®. Co. is also conducting preclinical research on next generation products, such as combined cell-matrix products for large bone defects and maxillofacial.

Hoffmann Green Cement Technologies SA

Hoffmann Green Cement Technologies SAS. Hoffmann Green Cement Technologies SAS is a France-based company, which manufactures cements. The Company mainly manufactures decarbonated cements for construction. Hoffmann Green Cement Technologies SAS is involved in the energy and ecological transition by manufacturing low carbon eco-materials.

ID Logistics Group

ID Logistics is an international contract logistics group that designs and implements one-stop services tailored to the specific requirements of each client. The services Co. offers combine customized architectures to allow clients to optimize their supply chain.

Pharming Group NV

Pharming is a specialty pharmaceutical company developing products for the treatment of rare diseases and unmet medical needs. Co.'s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (‘HAE') attacks in patients in Europe, the U.S., Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. RUCONEST® is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama, and Venezuela by Cytobioteck, in South Korea by HyupJin Corporation and in Israel by Megapharm.

Valbiotis SA

Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

Provider
Portzamparc Sponsored
Portzamparc Sponsored

​Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.

Analysts
Arnaud Despre

Clément Bassat

Maxence Dhoury

Mohamed Kaabouni

Nicolas Delmas

Other Reports on these Companies
Other Reports from Portzamparc Sponsored

ResearchPool Subscriptions

Get the most out of your insights

Get in touch